Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  TELA Bio, Inc.    TELA

TELA BIO, INC.

(TELA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

TELA BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/01/2020 | 07:18am EDT

Item 7.01 Regulation FD Disclosure.

On April 1, 2020, TELA Bio, Inc. (the "Company") updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.1, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits


The following exhibits are being filed herewith:



Exhibit
No.        Document
  99.1       Corporate Slide Deck, dated April 1, 2020.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on TELA BIO, INC.
05/29TELA Bio to Present at the Jefferies Virtual Healthcare Conference
GL
05/22TELA BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
05/15TELA BIO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
AQ
05/12TELA BIO, INC. : Results of Operations and Financial Condition, Financial Statem..
AQ
05/12TELA Bio Announces First Quarter 2020 Financial Results
GL
05/04TELA BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/28TELA Bio to Announce First Quarter 2020 Financial Results and Host Conference..
GL
04/23TELA BIO, INC. : Change in Directors or Principal Officers, Other Events, Financ..
AQ
04/23TELA Bio Announces Changes to its Board of Directors
GL
04/01TELA BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
More news
Financials (USD)
Sales 2020 15,8 M - -
Net income 2020 -25,2 M - -
Net Debt 2020 - - -
P/E ratio 2020 -7,75x
Yield 2020 -
Capitalization 194 M 194 M -
EV / Sales 2019
Capi. / Sales 2020 12,3x
Nbr of Employees 89
Free-Float 91,9%
Chart TELA BIO, INC.
Duration : Period :
TELA Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TELA BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 16,50 $
Last Close Price 17,00 $
Spread / Highest target 17,6%
Spread / Average Target -2,94%
Spread / Lowest Target -17,6%
EPS Revisions
Managers
NameTitle
Antony Koblish President, Chief Executive Officer & Director
Douglas G. Evans Chairman
Michael Leonard Vice President-Operations
Nora Brennan Chief Financial Officer
Maarten Persenaire Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
TELA BIO, INC.31.27%177
MEDTRONIC PLC-14.41%130 420
BAXTER INTERNATIONAL INC.8.20%46 294
HOYA CORPORATION-3.64%35 089
DEXCOM, INC.67.26%34 699
TERUMO CORPORATION10.19%29 791